...
首页> 外文期刊>Journal of cardiovascular magnetic resonance : >Safe performance of magnetic resonance of the heart in patients with magnetic resonance conditional pacemaker systems: the safety issue of the ESTIMATE study
【24h】

Safe performance of magnetic resonance of the heart in patients with magnetic resonance conditional pacemaker systems: the safety issue of the ESTIMATE study

机译:磁共振条件起搏器系统患者心脏磁共振的安全性能:ESTIMATE研究的安全性问题

获取原文

摘要

BackgroundNo published data exist about the safety of diagnostic magnetic resonance (MR) of the heart performed in a larger series of patients implanted with MR conditional pacemakers (PM). The purpose of our study is to analyse safety and potential alterations of electrical lead parameters in patients implanted with the EnRhythm/Advisa MRI SureScan PM with 5086MRI leads (Medtronic Inc.) during and after MR of the heart at 1.5 Tesla.MethodsPatients enrolled in this single center pilot study who underwent non-clinically indicated diagnostic MR of the heart were included in this analysis. Heart MR was performed for analyses of potential changes in right and left ventricular functional parameters under right ventricular pacing at 80 and 110 bpm. Atrial/ventricular sensing, atrial/ventricular pacing capture threshold [PCT], and pacing impedances were assessed immediately before, during, and immediately after MR, as well at 3 and 15 months post MR.ResultsThirty-six patients (mean age 69?±?13?years; high degree AV block 18 [50%]) underwent MR of the heart. No MR related adverse events occurred during MR or thereafter. Ventricular sensing differed significantly between the FU immediately after MR (10.3?±?5.3?mV) and the baseline FU (9.8?±?5.3?mV; p?
机译:背景技术尚无公开的数据表明,在接受MR条件起搏器(PM)植入的更多患者中进行心脏诊断性磁共振(MR)的安全性。我们的研究目的是分析在1.5特斯拉的心脏MR期间和之后植入EnRhythm / Advisa MRI SureScan PM和5086MRI导线(Medtronic Inc.)的患者的安全性和潜在的电导线参数变化。这项非中心性单中心试验研究接受了非临床指示的心脏诊断性MR。在80和110 bpm的右心室起搏下,对心脏MR进行分析,以分析右心室和左心室功能参数的潜在变化。在MR之前,期间和之后以及MR术后3个月和15个月时评估了心房/心室感觉,心房/心室起搏捕获阈值[PCT]和起搏阻抗。结果36例患者(平均年龄69岁± 13岁;高度房室传导阻滞18 [50%])经历了心脏MR。在MR期间或之后没有发生与MR相关的不良事件。 MR后立即发生的FU(10.3±±5.3?mV)和基线FU(9.8±±5.3?mV; p <0.05)之间的心室感觉有显着差异。尽管FU之间的PCT [V / 0.4ms]并没有显着差异(基线:0.84±0.27; MR扫描之间:0.82±0.27; MR之后立即:0.84±0.24; 3个月: 0.85±±0.23; 15个月:0.90±±0.67; p?=?ns),有7位患者(19%)在3个月时PCT升高了100%(最大PCT测量为1.0?V) FU与基线相比。与基线(508?±?75)相比,在MR扫描之间的FU(516?±?47)和15个月FU(482?±?58)时,RV起搏阻抗[?/ 5V]有显着差异。结论我们的研究结果表明,尽管有明显的但与临床无关的心室PCT改变,但在有条件的MR有条件的EnRhythm / Advisa系统患者中,心脏MR是安全的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号